Moreover, the restoration of immune function when targeting IFNαR via anifrolumab, a drug already approved and on market for non-renal SLE and in phase 3 trials for lupus nephritis, systemic sclerosis, idiopathic inflammatory myopathies, and cutaneous lupus erythematosus, highlights the potential therapeutic value of targeting type I IFN signaling in HIV infection to alleviate immune dysfunction and improve DC and T cell functionality. The gene discussed is IFNAR1; the disease is lupus nephritis.